The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas

Clinical Endocrinology

Volumn 53, Issue 1, 2000, Pages 53-60

  Di Sarno, Antonella ^a   Landi, Maria Luisa ^a   Marzullo, Paolo ^a   Di Somma, Carolina ^a   Pivonello, Rosario ^a   Cerbone, Gaetana ^a   Lombardi, Gaetano ^a   Colao, Annamaria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN; QUINAGOLIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; NAUSEA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROLACTINOMA; TREATMENT OUTCOME;

ADULT; AMINOQUINOLINES; CROSS-OVER STUDIES; DOPAMINE AGONISTS; ERGOLINES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; RECEPTORS, DOPAMINE D2; TREATMENT OUTCOME;

EID: 0033842111     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2000.01016.x     Document Type: Article

References (27)

1. Dopamine agonists and pituitary tumor shrinkage
2. Treatment of prolactin-secreting macroadenoma with once-a-week dopamine agonist cabergoline
3. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine
4. Cabergoline: A first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma
5. Effectiveness and tolerability of long-term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients
6. Treatment of prolactinomas
7. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage
8. Prolactinomas resistant to other dopamine agonists respond to chronic cabergoline treatment
9. Growth-hormone and prolactin excess
10. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinoma
11. Should dopamine agonists treatment for prolactinomas be life-long?
12. Long-lasting prolactin lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients
13. A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients
14. Comparison of the clinical activity of mesulergine and pergolide in the treatment of hyperprolactinaemia
15. Effects of a new prolactin inhibitor, CV 205-502, in the treatment of human macroprolactinomas
16. A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia
17. Bromocriptine-induced removal of endoplasmic membranes from prolactinoma cells
18. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas
19. Effect of oestrogen and bromocriptine on in vivo secretion and mitosis in prolactin cells
20. Therapeutic Controversy. Management of prolactinomas
21. Resistance to bromocriptine in prolactinomas
22. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine
23. Bromocriptine
24. Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients
25. Quinagolide efficacy and tolerability in hyperprolactinaemic patients who are resistant to or intolerant of bromocriptine
26. Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: A placebo controlled, double blind, multicentric study
27. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea